Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · IEX Real-Time Price · USD
1.740
+0.010 (0.58%)
At close: Jul 19, 2024, 4:00 PM
1.760
+0.020 (1.15%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $6.08M in the twelve months ending March 31, 2024, with 733.42% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.68M with 231.42% year-over-year growth. In the year 2023, Plus Therapeutics had annual revenue of $4.91M with 2,093.30% growth.
Revenue (ttm)
$6.08M
Revenue Growth
+733.42%
P/S Ratio
1.63
Revenue / Employee
$304,200
Employees
20
Market Cap
9.93M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
Dec 31, 2022 | 224.00K | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
Dec 31, 2019 | 7.00M | 4.02M | 134.60% |
Dec 31, 2018 | 2.98M | -3.43M | -53.47% |
Dec 31, 2017 | 6.41M | -4.97M | -43.66% |
Dec 31, 2016 | 11.38M | -279.00K | -2.39% |
Dec 31, 2015 | 11.66M | 4.06M | 53.45% |
Dec 31, 2014 | 7.60M | -4.60M | -37.70% |
Dec 31, 2013 | 12.20M | -2.31M | -15.90% |
Dec 31, 2012 | 14.50M | 4.51M | 45.07% |
Dec 31, 2011 | 10.00M | -631.00K | -5.94% |
Dec 31, 2010 | 10.63M | -4.10M | -27.85% |
Dec 31, 2009 | 14.73M | 7.88M | 114.94% |
Dec 31, 2008 | 6.85M | 804.00K | 13.29% |
Dec 31, 2007 | 6.05M | -1.88M | -23.69% |
Dec 31, 2006 | 7.93M | 1.92M | 32.01% |
Dec 31, 2005 | 6.01M | -813.00K | -11.92% |
Dec 31, 2004 | 6.82M | -7.27M | -51.60% |
Dec 31, 2003 | 14.09M | 4.92M | 53.70% |
Dec 31, 2002 | 9.17M | 3.52M | 62.29% |
Dec 31, 2001 | 5.65M | -603.00K | -9.65% |
Dec 31, 2000 | 6.25M | 4.74M | 313.15% |
Dec 31, 1999 | 1.51M | - | - |
Dec 31, 1998 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pieris Pharmaceuticals | 40.93M |
PAVmed | 3.02M |
Elevai Labs | 2.18M |
Mangoceuticals | 844.87K |
Inhibikase Therapeutics | 195.98K |
ABVC BioPharma | 25.36K |
PSTV News
- 20 days ago - Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT - GlobeNewsWire
- 2 months ago - Plus Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 - GlobeNewsWire
- 2 months ago - Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial - GlobeNewsWire
- 2 months ago - Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial - GlobeNewsWire
- 2 months ago - Plus Therapeutics Announces Private Placement Financing of up to $18 Million - GlobeNewsWire